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Abstract: Sublingual immunotherapy (SLIT) is a matter of only 20
years. Nonetheless, in this short period of time more than 60
randomized double blind placebo-controlled trials have been pub-
lished, in addition to postmarketing surveillance studies and meta-
analyses. The wide diffusion of SLIT in clinical practice and the
large availability of experimental data prompted the WAO to pub-
lish a position paper on SLIT, to identify the indications, contrain-
dications, and practical aspects of the treatment. On the basis of the
available literature, SLIT is certainly indicated in allergic rhinitis in
both adults and children. In this latter population, SLIT may exert a
preventative effect on the development of asthma. The age seems
not to represent a special problem. SLIT can be used also when
asthma is associated to rhinitis, whereas it is not the first choice for
the treatment of isolated asthma. The IgE-mediated mechanism and
the clear identification of the causal role of the allergen are manda-
tory prerequisites for prescribing SLIT. The safety profile is excel-
lent, but it is recommended that the first dose be given under medical
supervision. Atopic dermatitis, latex allergy, and hymenoptera hy-
persensitivity are promising fields of use of SLIT, but they are still
considered only experimental uses.
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INTRODUCTION
The subcutaneous modality of immunotherapy injections(SCIT) remained, for several decades, as the only avail-
able administration route, although it is burdened by a certain
risk of severe side effects. The problem of the risk/benefit
ratio prompted the search for safer administration routes
including the sublingual one, sublingual immunotherapy
(SLIT), which was first described in 1986.1 In less than 20
years, a very large amount of clinical data, controlled trials,
and postmarketing surveys on SLIT were published. As such,
SLIT progressively achieved credibility and was introduced
in the official documents as a viable alternative to the classic
injection route2,3 for both adults and children. Because of the
increasing utilization of SLIT in Europe and many other
countries worldwide, it was felt that a document or position
paper on its clinical use, safety aspect, and unmet needs was
necessary. For this reason, the World Allergy Organization
convened a meeting in Paris during January 2009 to prepare
and discuss a position paper. This was released as a draft
within June 2009 and subsequently endorsed by almost all the
national allergy societies and all the large regional societies.
The WAO-SLIT position paper was presented in the WAO
Journal4 just before the 2009 World Allergy Congress in
Buenos Aires and published as a supplement in Allergy in
December 2009.5
The document reviews the currently available literature
on SLIT, including efficacy, safety, mechanisms, impact on
the natural history, indications, methodology for clinical
trials, and unmet needs. From the clinician’s viewpoint, the
indications to SLIT and the choice of eligible patients is of
primary relevance. The indications suggested in the position
paper are derived as far as possible from the experimental
evidence available.
CLINICAL EFFICACY AND SAFETY: THE
LITERATURE
At the date of publication of the position paper there
were 60 randomized double blind placebo-controlled trials
performed with SLIT and various meta-analyses. The meta-
analyses included patients with rhinitis only,6 asthma only,7
and asthma and rhinitis in children.8,9 All the meta-analyses
concluded that there was a significant effect of SLIT versus
placebo. The reliability of the meta-analyses has been ques-
tioned10 especially on the basis of possible publication biases,
incorrect reporting of the data, and large heterogeneity of the
trials included. The problem of heterogeneity has been re-
peatedly highlighted as a drawback, but it is also true that
meta-analyses are intended to summarize the results of stud-
ies when they are not directly comparable to each other.
Furthermore, the mentioned meta-analyses pooled together
the studies with all allergenic extracts, whereas differences
may exist among allergens. In this regard, there is now a
meta-analysis restricted to house dust mite SLIT that shows a
significant effect on symptoms.11
The so-called “big trials” (for review4,5), conducted
with grass pollen extracts, provided relevant information on
the clinical use of SLIT. In particular, the clinical effect of
SLIT versus placebo was shown to range between 25% and
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50% when the cutoff for efficacy is set at 20%.12 More
importantly, the big trials demonstrated that the clinical effect
is to some extent dose-dependent and that the optimal main-
tenance dose for grass SLIT is around 30 times the corre-
sponding dose used with the injection route.
The effect in asthma is still a matter of debate because
some trials13–15 reported a marginal or no effect on asthma
symptoms. It is also true that the Dahl study13 was designed
to assess the safety, and in the Pham-Thi trial14 all the patients
(active and placebo) had no symptoms of asthma at baseline
nor during the trial and therefore no effect could be seen.
When patients with current asthma symptoms are studied, the
effect of SLIT can be detected. An early study16 in adults and
adolescents reported an improvement in quality of life and
respiratory function and a decrease in inhaled steroid use.
Three pediatric studies17–19 with mite SLIT found a signifi-
cant difference between active and placebo patients in day-
time and nighttime symptoms, and 1 study also demonstrated
a reduction in the eosinophil count.18 Those results were
recently replicated in another pediatric trial with grass
SLIT.20 Finally, in some studies, SLIT was shown capable of
reducing the degree of bronchial hyperresponsiveness.21,22
SLIT, similarly to SCIT, can prevent the onset of new
sensitizations,23 and also prevent the onset of asthma in
children with rhinitis.24,25 In addition, there are also 3 studies
that have demonstrated a long-lasting effect of SLIT after
discontinuation.26–28 Of note, the study by Durham et al28
deals with the follow-up at 1 year of the patients included in
one of the big trials.
Concerning the other possible indications of SLIT,
there are some controlled trials reporting a satisfactory effi-
cacy profile in latex allergy29,30 and in food allergy,31,32
whereas there is 1 single randomized controlled trial of SLIT
with house dust mite in children with atopic dermatitis.33 The
possible use of SLIT has been envisaged also in hymenoptera
venom allergy,34 but also in this case there is 1 single
controlled trial dealing with large local reactions.
The safety of SLIT is superior to that of SCIT,35 and no
fatality has been reported in 23 years of trials and clinical use.
The most frequently reported events were irritation of the
throat and oral itching. According to the recent data, the
number of side effects seems to be dose-dependent, as hap-
pens with SCIT. There are only 6 reports of anaphylaxis with
SLIT, although the occurrence of anaphylaxis at the first dose
would suggest the opportunity of giving the first dose under
medical supervision. In a recent report,36 2 severe reactions
(not anaphylactic shock) were described in 2 patients with
previous severe reactions to SCIT. Thus, caution should be
taken in patients with previous adverse events who are
switched to SLIT. Finally, some postmarketing surveys con-
firmed that the safety of SLIT does not change in children
younger than 5 years.37,38
INDICATIONS (TABLE 1)
It is mandatory that the IgE-mediated mechanism of the
disease (rhinitis or asthma) be clearly established, in addition
to the causal relationship between the exposure to allergen
and symptoms. This remains true for subcutaneous immuno-
therapy and for SLIT.
On the basis of the experimental evidence summarized
above, the indication to SLIT in allergic rhinitis is well
established in adults and children, independent of the allergen
considered. This also takes into account the very favorable
safety profile of SLIT. In addition, it can potentially modify
the disease and the clinical benefits may be sustained years
after discontinuation of treatment. Concerning asthma, SLIT
should be considered if symptoms are persistent, despite
pharmacological and nonpharmacological measures, or
when medications cause unacceptable side effects or patients
refuse to use inhaled corticosteroid. Also in this case immu-
notherapy should be considered only if there is clear evidence
of a relationship between symptoms and exposure to an
allergen to which the patient is sensitive. Similarly to SCIT,
also with SLIT severe/uncontrolled asthma is a contraindi-
cation. Patients allergic to mites may be candidates for SLIT
if they have significant symptoms of rhinitis or asthma when
they are exposed to domestic mite allergens.
Concerning children, SLIT is effective in allergic rhi-
nitis in children older than 5 years and may be safe in allergic
rhinitis in children older than 3 years. Thus, SLIT can be used
for allergic rhinitis in children with or without asthma but
should not be suggested as monotherapy for treating asthma.
Presently the use of SLIT in latex allergy, atopic
dermatitis, food allergy, and hymenoptera venom allergy is
under investigation, and more demonstrations are needed to
support the clinical use.
UNMET NEEDS
Some aspects of SLIT need to be elucidated, to provide
clinicians with clear and evidence-based recommendations
TABLE 1. Criteria of Selection for SLIT (Adapted From4,5)
● To be eligible for SLIT, patients should have the follow:
A clinical history of allergy.
Documented ALLERGEN-SPECIFIC IgE positive test.
The allergen used for immunotherapy must be clinically relevant to
their clinical history.
● Age does not seem to be a limitation.
● Monosensitized patients are ideal candidates for SLIT, and recently
single-allergen SLIT has been demonstrated to be effective in
polysensitized patients.
● Presently, use of SLIT in latex allergy, atopic dermatitis, food allergy,
and hymenoptera venom allergy is under investigation: more
demonstrations are needed to support clinical use.
● There is no indication whatsoever for treating non–IgE-mediated
hypersensitivity (i.e., nickel sensitivity) with SLIT.
● SLIT may be considered as initial treatment; failure of pharmacological
treatment is not an essential prerequisite for the use of SLIT.
● SLIT may be proposed as an early treatment in respiratory allergy
therapeutic strategy.
● Special SLIT indications exist in the following patients:
Patients uncontrolled with optimal pharmacotherapy (SCUAD).
Patients in whom pharmacotherapy induces undesirable side effects.
Patients refusing injections.
Patients who do not want to be on constant or long-term
pharmacotherapy.
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for the clinical use of the treatment. The most compelling
problem is the variability of the doses used in clinical trials
because both positive and negative results have been obtained
with both low and high doses and the dose interval for
efficacy is reported to range between 2 and 375 times the
amount given with SCIT. This is complicated by the vari-
ability in the protein content of the extracts by different
manufacturers.39 Only for grasses has an optimal dose been
identified in 15–25 g of major allergen per day, which is
roughly 50 times the monthly dose of SCIT. Dose-response
trials and the identification of the optimal maintenance dose
are needed at least for the more relevant allergens. From a
clinical point of view, there is no consensus on which is the
best administration regimen among the pre-seasonal, co-
seasonal, pre–co-seasonal, or continuous. It is true that, for
pollen allergens, most of the trials used a pre–co-seasonal
regimen,40 but this cannot be immediately extrapolated to all
extracts and to all patients. Similarly, the usefulness of a
build-up phase is still a matter of debate.
Finally, it is mandatory that all future trials be properly
designed, with a sample size calculation and with clearly
established outcomes,41,42 permitting better standardization of
treatment and providing clinicians with more univocal guide-
lines in the near future.
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